Phase 1b Open-label, Dose-Identification Study of XPro1595 in Patients with Mild to Moderate Alzheimer's Disease with Elevated high sensitivity C-reactive protein in Blood.

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Burn, Katherine, (Project Manager)
  • Woodward, Michael (Chief Investigator (CI))
  • Lai, Rosalyn (Chief Investigator (CI))
  • Clarnette, Roger (Chief Investigator (CI))
  • Brodtmann, Amy (Chief Investigator (CI))
  • Nestor, Peter J (Chief Investigator (CI))

Project: Research

StatusActive
Effective start/end date25/09/19 → 30/04/20
View all
View less

Keywords

  • Neuroscience
  • Alzheimer's disease
  • Clinical trial